Hormonal
Adopting a low glycaemic index (GI) diet improves glycaemic control (lower HbA1c and fasting glucose) and reduces insulin requirements in patients with type 1 and type 2 diabetes compared to standard or high-GI diets.
For diabetic patients, replacing high-glycaemic index carbohydrates (like white bread and potatoes) with low-glycaemic index options (like pulses and legumes) is a highly effective dietary strategy. This swap significantly lowers HbA1c, reduces daily insulin needs, and stabilizes blood glucose levels without requiring drastic calorie restriction.
A meta-analysis of eleven studies... lists the following improvements after a low-GI diet: a 16 % decrease in mean blood glucose levels, a 20 % decrease in urinary C-peptide, a 9 % fall of Hb A1c... A low-GI diet was found to induce a small but significant decrease in glucose profile... A decrease in insulin requirements was also found in another group of IDDM patients
Why this rating
Supported by a meta-analysis of 11 studies, large epidemiological studies (EURODIAB), and multiple randomized crossover trials.
Source
Health benefits of low glycaemic index foods, such as pulses, in diabetic patients and healthy individuals
Salwa W. Rizkalla et al. · British Journal Of Nutrition · 2002
DOI 10.1079/bjn2002715
More from this paper
- A low glycaemic index (GI) diet improves lipid profiles (lower total cholesterol, triglycerides, and VLDL; higher HDL) and reduces cardiovascular disease risk in both diabetic and healthy individuals.Good
- A low glycaemic index (GI) diet increases satiety and reduces voluntary energy intake, facilitating weight loss and fat mass reduction in overweight and obese individuals.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →